# Renovo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renovo

- Industry: Pharmaceuticals
- Headquarters: Manchester, UK
- Website: www.renovo.com
- Total disclosed funding: $48M
- Latest round: Series B (Jan 31, 2003)
- Investors on record: 6

## About

Renovo Ltd. specializes in providing advanced digital solutions for brand management, focusing on enhancing online visibility and performance for businesses across various sectors.Renovo Ltd. is a digital solutions provider that enhances brand management through innovative online tools. The company is headquartered in Manchester, UK. It has undergone significant changes, notably launching its IPO in April 2006, raising GBP 50 million. There are no known subsidiaries or parent companies. The founder’s history is not publicly detailed, and no prior companies are mentioned. Renovo has engaged in a total of 5 deals, with its most recent deal occurring on April 7, 2006.Renovo Ltd. offers a comprehensive suite of digital solutions tailored for brand management. The core offering includes a user-friendly platform that enables businesses to market their products efficiently across digital channels. This platform features integration of brand assets, analytics tools, and customer engagement functionalities, addressing challenges in brand visibility and market penetration. Renovo targets a diverse clientele from small to medium-sized enterprises (SMEs) to larger corporations, providing solutions available across North America, Europe, and parts of Asia.In the most recent financial year of 2012, Renovo Ltd. reported a revenue of GBP 0.00. The EBITDA for the same year was GBP 0.00, indicating no earnings before interest, taxes, depreciation, and amortization during that period.Renovo Ltd. plans to continue expanding its offerings by launching new products aimed at enhancing brand management capabilities. The company intends to target new geographic markets, though specific regions and timelines for these expansions have not been publicly disclosed. The proceeds from the recently completed IPO in April 2006, amounting to GBP 50 million, are expected to support these upcoming initiatives.

## Funding rounds

- Series B, Jan 31, 2003, $3.2M — Temasek Holdings, BioVeda Capital
- Series B, Dec 2, 2002, $33M — Atlas Venture, Care Capital, HealthCap, JP Morgan Asset Management
- Series A, Nov 1, 2000, $12M — Atlas Venture, JP Morgan Asset Management

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series A, Series B
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series B
- HealthCap — Series B
- Temasek Holdings — Series B
- BioVeda Capital (https://capitalatlas.ai/funds/bioveda-capital) — Series B